secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021087
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q4 net loss $42.8M; ziftomenib KOMET-001 enrollment on track for mid-2024
--------------------------------------------------------------------------------

- Net loss for Q4 2023 was $42.8M vs $33.1M in Q4 2022; full year loss $152.6M vs $135.8M.
- Cash and investments $424M at Dec 31, 2023; pro forma $570M after Jan 2024 private placement, runway into 2027.
- Enrollment of 85 patients in registration-directed KOMET-001 trial of ziftomenib for NPM1-m AML expected by mid-2024.
- Preliminary KOMET-007 data: 100% CR in frontline NPM1-m/KMT2A-r AML with 7+3; 53% ORR in R/R with ven/aza; no differentiation syndrome.
- First patient dosed in KOMET-008 (ziftomenib + gilteritinib, FLAG-IDA or LDAC); collaboration with Mirati for KO-2806 + adagrasib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/0000950170-24-021087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/kura-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer